76% Say Genomind’s Genetic Test Influenced Treatment, 67% Elected to Make Changes to Treatment, and 87% Increased Their Confidence in Treatment Decisions
October 3, 2011 – Chalfont, Pennsylvania – Genomind, LLC, a company focused on neuropsychiatric personalized medicine, today announced data from a new study at the 2011 Autumn Conference of The International Society for CNS Clinical Trials and Methodology (ISCTM). The presentation, entitled, “Does Pharmacogenetic Testing in Psychiatry Influence Clinician Treatment Selection and Confidence?” indicates that 76% of early adopter clinicians say that the Genecept™ Assay influenced their treatment of patients, 67% say they elected to make changes to treatment, and 87% say the test increased their confidence in treatment decisions.
“We are pleased to be able to present our data at ISCTM about how genetic testing can help clinicians be more confident about the treatment decisions they make,” said Jay Lombard, DO, Chief Scientific Officer for Genomind. “As opposed to trial and error, a personalized medicine approach has great promise for making better choices about treatment, and we anticipate seeing further data that will support the results from our early adopter program.”
The study was a cross-sectional analysis of clinician surveys. Participant clinicians were selected through outreach to licensed practitioner members of the Neuroscience Education Institute (NEI), a provider of continuing education to mental health professionals around the world. In the initial round, 69 clinicians returned responses to Genomind’s Clinical Decision Surveys, reporting their experience with 105 patients.
Those 105 patients were notable for the severity and chronicity of illness: 39% were reported as having had four or more previous treatment trials, and more than 1/3 had been ill consistently for more than 4 years.
Genomind has also initiated pilot studies with leading industry partners to further demonstrate clinical utility, efficacy outcomes, and cost savings from the use of the Genecept Assay.
ISCTM, The International Society for CNS Clinical Trials and Methodology, is a multi-disciplinary independent organization, devoted to promoting advances that address strategic clinical, regulatory, methodological, and policy challenges that arise in the development and use of central nervous system (CNS) therapeutics. The work is accomplished through partnerships with persons in academia, industry, government, policy-making, and the public. Learn more at http://www.isctm.org.
NEI, the Neuroscience Education Institute, was founded in 2000 by award-winning author and psychiatrist Stephen M. Stahl, MD. NEI provides interactive learning to mental health clinicians worldwide. Through NEI’s fast-growing Global Psychopharmacology Congress, its web-based CME activities, and its online resources, NEI simplifies complex concepts to enhance understanding for US and international clinicians. NEI Members and Guests have access to http://www.NEIglobal.com, an online resource focused on the essentials of psychopharmacology. Learn more at http://www.NEIglobal.com.
Genomind is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of personalized medicine into psychiatry by providing genetic information to better understand the patient. Its Genecept™ Assay was made available for the study. Genomind was founded by Ronald I Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health and bringing innovations in science, delivery, and access to mental health patients. He also is founder of ValueOptions, one of the nation’s leading behavioral health and wellness companies. Dr Lombard, a neurologist, is co-founder of Genomind and is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more athttp://www.genomind.com.
Marketing Manager, Genomind